3D-pharmacophore analyses of transporter ligands for drug discovery studies in consideration of pharmacokinetics

考虑药代动力学的药物发现研究中转运蛋白配体的 3D 药效团分析

• 批准号: 18590037
• 负责人: HIRONO Shuichi
• 金额: $ 2.55万
• 依托单位: Kitasato University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18590037/
• 关键词: 3D-QSAR; Ligand-Based Drug Design; Transporter; 3D-pharmacophore; Pharmacokinetics; in silico screening

It is important for the effective drug design and discovery to consider the optimization of the pharmacokinetics from the initial stage of pharmaceutical developments. It is a key point in the current rational drug design and development to identify three-dimensional pharmacophores of the transporter ligands and analyze transporter-ligand interaction, because the transporter proteins express on various histionic cell membranes such as gastrointestinal, brain, liver, kidney to play an important role for the transport of drugs.In this study, we utilized the ligand-based drug design techniques developed in our laboratory to analyze three-dimensional quantitative structure-activity relationships (3D-QSAR) for the ligands of human Organic Cation Transporter 1 (hOCT1) and carry out the comparative study with a 3D-QSAR model generated from other methods. As a result, we were able to get the 3D-QSAR model with a good statistic (q^2 value) by analysis using our techniques. The three-dimensional pharmacophore of hOCT1 ligand obtained from this study consists of a hydrogen bond donor and three hydrophobic atomic groups. This three-dimensional pharmacophore is similar to one obtained from the other methods, but it is shown that our 3D-QSAR model is statistically better than one from other methods for the data set (test set) to evaluate the quality of the model. Thus it is thought that our 3D-QSAR model is a fine model with high predictivity of biological activity for non-homologous compounds which have various structures.

从药物开发的初始阶段就考虑药物动力学的最优化，对于有效的药物设计和发现是非常重要的。由于转运蛋白在胃肠道、脑、肝、肾等多种组织细胞膜上的表达对药物的转运起着重要作用，识别转运体配体的三维药效团并分析转运体与配体的相互作用是当前合理药物设计和开发的关键。本研究利用本实验室开发的基于配体的药物设计技术对人有机阳离子转运体1(HOCT1)的配体进行了三维定量构效关系(3D-QSAR)分析，并与其他方法建立的3D-QSAR模型进行了比较研究。因此，我们能够通过使用我们的技术进行分析，得到具有良好统计量(Q^2值)的3D-QSAR模型。本研究得到的hOCT1配体的三维药效团由一个氢键供体和三个疏水原子基团组成。该三维药效团与其他方法获得的三维药效团相似，但研究表明，对于数据集(测试集)，我们的3D-QSAR模型在统计上优于其他方法来评估模型的质量。因此，我们的3D-QSAR模型被认为是一个对具有不同结构的非同源化合物具有很高生物活性预测能力的精细模型。